Extended-release amantadine may improve levodopa dyskinesia control
VANCOUVER – An extended-release amantadine formulation reduced levodopa-induced dyskinesia in a phase III Parkinson’s disease trial from the drug’s developer, Adamas Pharmaceuticals.
Amantadine...
Source: Clinical Neurology News - Category: Neurology Source Type: news